Get the Stockscreener App
2.69
1.51%
0.04
After Hours:
2.71
0.02
+0.74%
Lisata Therapeutics Inc stock is traded at $2.69, with a volume of 2,149.
It is up +1.51% in the last 24 hours and up +16.96% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$2.65
Open:
$2.7485
24h Volume:
2,149
Relative Volume:
0.18
Market Cap:
$22.44M
Revenue:
-
Net Income/Loss:
$-20.74M
P/E Ratio:
-1.0717
EPS:
-2.51
Net Cash Flow:
$-18.90M
1W Performance:
+3.05%
1M Performance:
+16.96%
6M Performance:
-0.77%
1Y Performance:
-14.19%
1-Day Range:
$2.69
$2.7491
1-Week Range:
$2.51
$2.80
52-Week Range:
$1.87
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.69 | 22.44M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Dimensional Fund Advisors LP Increases Stock Position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Lisata outlines data-rich year ahead with multiple clinical milestones for Certepetide - MSN
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics’ Earnings Call Highlights Progress - TipRanks
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... - Yahoo Finance
Earnings call transcript: Lisata Therapeutics sees improved Q1 2025 performance - Investing.com
Lisata Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum - Proactive financial news
Lisata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 - The Manila Times
Lisata Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely? - Yahoo Finance
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.9% – Still a Buy? - Defense World
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalant license agreement - Proactive financial news
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive Investors
Market movers: Meta, HPE, Applied Digital, Lisata Therapeutics... - Proactive Investors
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’ - marketscreener.com
Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com Australia
Neostem stock plunges to 52-week low at $2.01 amid market challenges By Investing.com - Investing.com South Africa
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025 - Proactive financial news
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR.com
Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors
Lisata Therapeutics expands drug discovery with GATC AI collaboration - Proactive Investors USA
Lisata Therapeutics expands drug discovery with GATC AI collaboration | NASDAQ:LSTA - Proactive Investors
Lisata Therapeutics to Present at the Investival Showcase USA - The Manila Times
Can This Clinical-Stage Pharma Company Transform Solid Tumor Treatment? CEO Presents Next Month - StockTitan
Lisata Therapeutics and GATC Health Consummate First Step - GlobeNewswire
Market movers: General Motors, Moderna, CrowdStrike, Lisata... - Proactive Investors UK
Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology - Nasdaq
Lisata Therapeutics partners with GATC Health to advance AI-driven drug development - Proactive Investors UK
Can AI Revolutionize Lisata's Pancreatic Cancer Drug? New GATC Health Partnership Aims to Prove It - StockTitan
Neostem stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):